This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (34)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Endocrine Diseases  • Thyroid/ Parathyroid Diseases  • Endocrine Surgery  • Endoscopy/ Minimally Invasive Surgery  • Otolaryngology/ Head & Neck Surgery  • Alert me on articles by topic

Mayo Clinic Experience

Clive S. Grant, MD; Geoffrey Thompson, MD; David Farley, MD; Jon van Heerden, MB

Arch Surg. 2005;140:472-479.

Hypothesis  Minimally invasive parathyroidectomy (MIP) for primary hyperparathyroidism (HPT) has equal cure and recurrence rates as standard cervical exploration. Changes in the management of primary HPT have occurred since introducing MIP including localization, anesthesia, intraoperative parathyroid hormone monitoring, and indications for parathyroidectomy.

Design  Cohort analysis of 1361 consecutive patients with primary HPT operated on at the Mayo Clinic, Rochester, Minn, from June 1998 through March 2004. Mean follow-up, 25 months.

Setting  Tertiary referral center.

Patients  One thousand three hundred sixty-one patients operated on for primary HPT, excluding 160 patients who were reoperated on.

Intervention  Standard cervical exploration MIP.

Main Outcome Measures  Cure, recurrence, localization, anesthesia, hospitalization, intraoperative parathyroid hormone level monitoring, contraindications to MIP, surgical indications, assessment of osteoporosis and osteopenia, postoperative patient assessment of general patient health, and operative satisfaction.

Results  Cure of primary HPT for both conventional exploration and MIP was 97%; only 1 patient who underwent MIP had a potential recurrence. Imaging sensitivity and positive predictive values were as follows: sestamibi scintigraphy, 86% and 93%; ultrasonography, 61% and 87%, respectively. Usage of general vs local anesthesia with intravenous sedation was 46% and 49%, respectively, in patients w ho underwent MIP; 46% were dismissed as outpatients, 49% had single-night stays. The accuracy of intraoperative parathyroid hormone level monitoring was as follows: 98% (8% had true-negative results); the frequency of multiple gland disease was 13%. Accounting for causes precluding MIP, an estimated 60% to 70% of all patients would be eligible for MIP. By preoperative assessment, 79% had osteoporosis-osteopenia; 58% with postoperative bone mineral density measurements were improved. More than 85% were satisfied with the results of their operation.

Conclusion  With high-quality localization and intraoperative parathyroid hormone level monitoring, MIP can be performed with equal cure rates as standard cervical exploration, with no present evidence of delayed recurrence.

Author Affiliations: Department of Surgery, Mayo Clinic, Rochester, Minn.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Surgery for Hyperparathyroidism in Image-Negative Patients
Chan et al.
Arch Surg 2008;143:335-337.
ABSTRACT | FULL TEXT  

Value of Intraoperative Parathyroid Hormone Monitoring
Sharma et al.
Ann. Surg. Oncol. 2008;15:493-498.
ABSTRACT | FULL TEXT  

Comparison of SPECT/CT, SPECT, and Planar Imaging with Single- and Dual-Phase 99mTc-Sestamibi Parathyroid Scintigraphy
Lavely et al.
JNM 2007;48:1084-1089.
ABSTRACT | FULL TEXT  

Parathyroid Imaging: Technique and Role in the Preoperative Evaluation of Primary Hyperparathyroidism
Johnson et al.
Am. J. Roentgenol. 2007;188:1706-1715.
ABSTRACT | FULL TEXT  

Predictors of Single-Gland vs Multigland Parathyroid Disease in Primary Hyperparathyroidism: A Simple and Accurate Scoring Model
Kebebew et al.
Arch Surg 2006;141:777-782.
ABSTRACT | FULL TEXT  

Unilateral Cervical Surgical Exploration Aided by Intraoperative Parathyroid Hormone Monitoring in Patients With Primary Hyperparathyroidism and Equivocal Sestamibi Scan Results
Goldstein et al.
Arch Surg 2006;141:552-559.
ABSTRACT | FULL TEXT